Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (8570)	9/29/1998 9:35:00 AM
From: Leman	Read Replies (1) \| Respond to of 8798

Tuesday September 29, 8:43 am Eastern Time Company Press Release SOURCE: Biomerica, Inc. Biomerica Receives U.S. FDA Clearance To Market Its New Thyroid Disease Test NEWPORT BEACH, Calif., Sept. 29 /PRNewswire/ -- Biomerica, Inc. (Nasdaq: BMRA - news) today announced that the U.S. Food and Drug Administration (FDA) cleared to market its new free T4 enzyme immunoassay test. The new test completes the Company's line of thyroid endocrinology products. The estimated worldwide market for all thyroid testing is approximately $600 million. Biomerica now has a complete panel, including six FDA cleared tests, to accurately determine thyroid dysfunction. This newest product determines the amount of free thyroxin (T4) circulating in the bloodstream, a significant aid in the assessment of thyroid diseases. The panel of thyroid tests, developed and produced by Biomerica, is important in determining and monitoring the presence of Graves' disease, Hashimoto's thyroiditis and primary thyroid failure. ''This is an important addition to Biomerica's thyroid product line. In the U.S. free T4 is one of the two major thyroid tests used in most clinical situations,'' said Biomerica's CEO Zackary S. Irani. ''We are committed to bringing new products to market quickly, efficiently and cost effectively. This product complements our line of unique medical diagnostic tests for the laboratory.'' Biomerica's free T4 product is sensitive, highly specific, and cost effective, utilizing an industry standard microwell format capable of determining results of 45 patient samples simultaneously. In addition, the product does not utilize radioactivity, simplifying the handling of the test and eliminating radioactive waste. Biomerica's thyroid endocrinology panel of tests has the flexibility of use in a variety of laboratories for manual testing and automation. Biomerica (Nasdaq: BMRA - news) is a global medical company devoted to developing, manufacturing and marketing advanced medical diagnostic products for the early detection of diseases. The products are used in hospitals, physician's offices and in the home for self-testing.